Acticor Biotech SAS
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Pha… Read more
Acticor Biotech SAS (ALACT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 1.021x
Based on the latest financial reports, Acticor Biotech SAS (ALACT) has a cash flow conversion efficiency ratio of 1.021x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.43 Million) by net assets (€-5.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Acticor Biotech SAS - Cash Flow Conversion Efficiency Trend (2009–2023)
This chart illustrates how Acticor Biotech SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Acticor Biotech SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acticor Biotech SAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aruma Resources Ltd
AU:AAJ
|
-0.265x |
|
TVD Holdings PCL
BK:TVDH
|
-0.013x |
|
Star Vault AB (publ)
PINK:SRVTF
|
0.075x |
|
2F5
F:2F5
|
-0.137x |
|
Visionary Gold Corp
PINK:VIZNF
|
-0.015x |
|
Deltamac Taiwan Co Ltd
TWO:6144
|
-0.001x |
|
Dolphin International Bhd
KLSE:5265
|
-0.004x |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
-0.106x |
Annual Cash Flow Conversion Efficiency for Acticor Biotech SAS (2009–2023)
The table below shows the annual cash flow conversion efficiency of Acticor Biotech SAS from 2009 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €-5.31 Million | €-13.02 Million | 2.450x | -54.59% |
| 2022-12-31 | €-2.24 Million | €-12.10 Million | 5.396x | +532.41% |
| 2021-12-31 | €11.02 Million | €-13.75 Million | -1.248x | +68.23% |
| 2020-12-31 | €1.72 Million | €-6.74 Million | -3.928x | -729.73% |
| 2019-12-31 | €9.03 Million | €-4.28 Million | -0.473x | +46.07% |
| 2018-12-31 | €6.24 Million | €-5.47 Million | -0.878x | -2288.08% |
| 2017-12-31 | €-4.04 Million | €-162.12K | 0.040x | -2.36% |
| 2016-12-31 | €16.64 Million | €683.84K | 0.041x | +127.04% |
| 2015-12-31 | €17.11 Million | €-2.60 Million | -0.152x | -167.98% |
| 2014-12-31 | €18.47 Million | €4.13 Million | 0.224x | +162.03% |
| 2013-12-31 | €19.44 Million | €1.66 Million | 0.085x | -53.90% |
| 2012-12-31 | €17.69 Million | €3.27 Million | 0.185x | +227.37% |
| 2011-12-31 | €15.49 Million | €875.50K | 0.057x | -85.96% |
| 2010-12-31 | €2.06 Million | €829.82K | 0.403x | +27956.23% |
| 2009-12-31 | €1.39 Million | €2.00K | 0.001x | -- |